Therapeutic drug monitoring in antituberculosis chemotherapy: Clinical perspectives

Clinica Chimica Acta

Volumn 313, Issue 1-2, 2001, Pages 31-36

  Yew, W W ^a  

^a GRANTHAM HOSPITAL   (Hong Kong)

Author keywords

Antituberculosis chemotherapy; Drug disease interaction; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

ANTACID AGENT; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; CYCLOSERINE; DELAVIRDINE; EFAVIRENZ; ETHAMBUTOL; FERROUS SULFATE; INDINAVIR; ISONIAZID; LEVODOPA; MULTIVITAMIN; NELFINAVIR; OFLOXACIN; PARACETAMOL; PHENYTOIN; PROTEINASE INHIBITOR; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAMYCIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STREPTOMYCIN; SUCRALFATE; THEOPHYLLINE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; WARFARIN;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG MONITORING; DRUG OVERDOSE; DRUG SCREENING; EMPYEMA; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPROTHROMBINEMIA; INTOXICATION; LIVER TOXICITY; MALABSORPTION; NEUROTOXICITY; PATIENT CARE; PRIORITY JOURNAL; TOXICITY; TREATMENT FAILURE; TUBERCULOSIS; TUBERCULOUS MENINGITIS; UVEITIS;

ANTITUBERCULAR AGENTS; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; TUBERCULOSIS;

EID: 0034748637     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00646-5     Document Type: Conference Paper

References (38)

1. Using therapeutic drug monitoring to dose the antimycobacterial drugs
2. Clinical pharmacokinetics of the anti-tuberculosis drugs
3. Serum pharmacokinetics of antimycobacterial drugs in patients with multidrug-resistant tuberculosis during therapy
4. Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea
5. Reduced plasma concentrations of anti-tuberculosis drugs in patients with HIV infection
6. Low serum antimycobacterial drug concentrations in non-HIV-infected tuberculosis patients
7. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after co-administration of cycloserine and ofloxacin
8. Levofloxacin in the treatment of drug-resistant tuberculosis
9. Pharmacology of the antimycobacterial drugs
10. Chronic tuberculous empyema with bronchopleural fistula resulting in treatment failure and progressive drug resistance
11. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema
12. Liquid chromatographic assay for simultaneous determination of pyrazinamide and rifampicin in serum samples from patients with tuberculous meningitis
13. Clinically significant drug interactions with anti-tuberculosis agents
14. Recent advances: The cytochrome P450 enzymes
15. Update on rifampin drug interactions
16. Update on rifampin drug interactions II
17. Update on rifampin drug interactions III
18. Isoniazid drug and food interactions
19. Severe acetaminophen toxicity in a patient receiving isoniazid
20. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease
21. Drug interactions with fluoroquinolones
22. Cations in the didanosine tablet reduce ciprofloxacin bioavailability
23. Tuberculosis in patients with human immunodeficiency virus infection
24. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis
25. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
26. Chemotherapy of tuberculosis for patients with renal impairment
27. Ofloxacin: A reappraisal of its antimicrobial activity, pharmacology and therapeutic use
28. Use of drugs in patients with renal failure
29. Ofloxacin pharmacokinetics in chronic renal failure and dialysis
30. Risk factors for hepatotoxicity from anti-tuberculosis drugs: A case-control study
31. Slow N-acetyl transferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity
32. Toxic hepatitis with isoniazid and rifampin: A meta-analysis
33. Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease
34. Blood concentrations of rifampicin, desacetyl rifampicin, and isoniazid during combined therapy
35. Antituberculosis drug-induced hepatotoxicity. The role of Hepatitis C virus and the human immunodeficiency virus
36. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection
37. The promise and reality of fixed dose combinations with rifampicin
38. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market